US Patent

US7964592 — 2,4-di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Composition of Matter · Assigned to Novartis AG · Expires 2028-04-29 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel pyrimidine derivatives and their use as pharmaceuticals, including their production and compositions.

USPTO Abstract

Novel pyrimidine derivatives of formula I to process for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.

Drugs covered by this patent

Patent Metadata

Patent number
US7964592
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-04-29
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.